AGM Information • Oct 30, 2020
AGM Information
Open in ViewerOpens in native device viewer
In accordance with the principles of the Nomination Committee of Xbrane Biopharma AB ("Company" or "Xbrane"), adopted at the Annual General Meeting ("AGM") on 14 May 2020, the Nomination Committee shall consist of four members of whom three shall be nominated by the Company´s three largest shareholders with respect of voting power as of September 30, 2020. The fourth member shall be the chairman of the board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.
Based on the above, the Nomination Committee for the AGM in 2021 has been set up to consist of the following persons, which together represent approximately 33 percent of the number of shares and votes in the Company as of September 30, 2020:
Saeid Esmaeilzadeh has been appointed as chairman of the Nomination Committee.
The task of the Nomination Committee is prior to AGM prepare and submit proposals regarding the Chairman of the AGM, candidates for the post of chairman and other directors of the board, fees and other remuneration for board work to each director, fees to members of committees within the board, election and remuneration of the Company auditor and principles for the nomination committee.
The Nomination Committee's proposal will be presented in the notice to the AGM 2021 and on the Company's website, www.xbrane.com.
Shareholders may submit proposals to the Nomination Committee for the AGM on May 6, 2021 until January 15, 2021. The proposals can be sent to the following address: Xbrane Biopharma AB Nomination Committee, c/o Xbrane Biopharma AB, Banvaktsvägen 22, 171 48 Solna, Sweden, or via email: [email protected].
Xbrane's Annual General Meeting will be held in Stockholm on May 6, 2021.
Anders Tullgren, Chairman of the board E: [email protected]
Martin Åmark, Chief Executive Officer M: +46(0) 763-093 777 E: [email protected]
Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.